Piper Jaffray Companies assumed coverage on shares of Milestone Pharmaceuticals (NASDAQ:MIST) in a report released on Monday, June 3rd, BenzingaRatingsTable reports. The brokerage issued an overweight rating and a $26.50 price objective on the stock. Piper Jaffray Companies also issued estimates for Milestone Pharmaceuticals’ Q2 2019 earnings at ($0.70) EPS, Q3 2019 earnings at ($0.44) EPS, Q4 2019 earnings at ($0.51) EPS, FY2019 earnings at ($2.74) EPS, Q1 2020 earnings at ($0.51) EPS, Q2 2020 earnings at ($0.59) EPS, Q3 2020 earnings at ($0.58) EPS, Q4 2020 earnings at ($0.62) EPS and FY2020 earnings at ($2.30) EPS.
Separately, Cowen assumed coverage on Milestone Pharmaceuticals in a research note on Monday, June 3rd. They issued an outperform rating and a $32.00 price target for the company. Five investment analysts have rated the stock with a buy rating, The stock currently has an average rating of Buy and an average target price of $30.10.
Shares of NASDAQ MIST traded up $0.21 during midday trading on Monday, hitting $22.46. 15,300 shares of the stock traded hands, compared to its average volume of 55,585. Milestone Pharmaceuticals has a one year low of $15.09 and a one year high of $25.50. The stock has a 50-day moving average price of $20.44.
In related news, major shareholder Rtw Investments, Lp bought 666,667 shares of Milestone Pharmaceuticals stock in a transaction dated Thursday, May 9th. The shares were acquired at an average cost of $15.00 per share, with a total value of $10,000,005.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Holdings A/S Novo bought 333,333 shares of Milestone Pharmaceuticals stock in a transaction dated Monday, May 13th. The shares were bought at an average cost of $15.00 per share, for a total transaction of $4,999,995.00. The disclosure for this purchase can be found here.
Milestone Pharmaceuticals Company Profile
Milestone Pharmaceuticals Inc, a biopharmaceutical company, develops and commercializes drugs for the treatment of cardiovascular indications. It offers Etripamil that completed Phase 2 clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada, as well as for treating Atrial Fibrillation and Angina.
Featured Article: P/E Growth (PEG)
Receive News & Ratings for Milestone Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Milestone Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.